135 related articles for article (PubMed ID: 12782574)
1. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
Ianzano ML; Croci S; Nicoletti G; Palladini A; Landuzzi L; Grosso V; Ranieri D; Dall'Ora M; Santeramo I; Urbini M; De Giovanni C; Lollini PL; Nanni P
Oncotarget; 2014 Jan; 5(1):108-19. PubMed ID: 24334679
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX
Oncogene; 2001 Mar; 20(12):1445-54. PubMed ID: 11313888
[TBL] [Abstract][Full Text] [Related]
4. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
[TBL] [Abstract][Full Text] [Related]
5. Immunological prevention of a multigene cancer syndrome.
Croci S; Nicoletti G; Landuzzi L; De Giovanni C; Astolfi A; Marini C; Di Carlo E; Musiani P; Forni G; Nanni P; Lollini PL
Cancer Res; 2004 Nov; 64(22):8428-34. PubMed ID: 15548714
[TBL] [Abstract][Full Text] [Related]
6. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
[TBL] [Abstract][Full Text] [Related]
7. p53 and Her-2/neu in juvenile angiofibromas.
Schick B; Veldung B; Wemmert S; Jung V; Montenarh M; Meese E; Urbschat S
Oncol Rep; 2005 Mar; 13(3):453-7. PubMed ID: 15706416
[TBL] [Abstract][Full Text] [Related]
8. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
9. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
Duan W; Ding H; Subler MA; Zhu WG; Zhang H; Stoner GD; Windle JJ; Otterson GA; Villalona-Calero MA
Oncogene; 2002 Nov; 21(51):7831-8. PubMed ID: 12420220
[TBL] [Abstract][Full Text] [Related]
10. Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.
Izzotti A; Cartiglia C; Longobardi M; Bagnasco M; Merello A; You M; Lubet RA; De Flora S
Cancer Res; 2004 Dec; 64(23):8566-72. PubMed ID: 15574763
[TBL] [Abstract][Full Text] [Related]
11. [Rhabdomyosarcoma development in Trp53/fos mutant mice: tumor suppressor functions of the Fos protooncogene].
Jochum W
Verh Dtsch Ges Pathol; 2004; 88():224-30. PubMed ID: 16892556
[TBL] [Abstract][Full Text] [Related]
12. Targeted inactivation of p53 in human cells does not result in aneuploidy.
Bunz F; Fauth C; Speicher MR; Dutriaux A; Sedivy JM; Kinzler KW; Vogelstein B; Lengauer C
Cancer Res; 2002 Feb; 62(4):1129-33. PubMed ID: 11861393
[TBL] [Abstract][Full Text] [Related]
13. p53 family members in myogenic differentiation and rhabdomyosarcoma development.
Cam H; Griesmann H; Beitzinger M; Hofmann L; Beinoraviciute-Kellner R; Sauer M; Hüttinger-Kirchhof N; Oswald C; Friedl P; Gattenlöhner S; Burek C; Rosenwald A; Stiewe T
Cancer Cell; 2006 Oct; 10(4):281-93. PubMed ID: 17045206
[TBL] [Abstract][Full Text] [Related]
14. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
15. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
16. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.
Tsumura H; Yoshida T; Saito H; Imanaka-Yoshida K; Suzuki N
Oncogene; 2006 Dec; 25(59):7673-9. PubMed ID: 16785989
[TBL] [Abstract][Full Text] [Related]
17. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.
Hayakawa Y; Rovero S; Forni G; Smyth MJ
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9464-9. PubMed ID: 12867593
[TBL] [Abstract][Full Text] [Related]
18. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
